Review of tenofovir-emtricitabine
Authors Saba Woldemichael Masho, Cun-Lin Wang, Daniel E Nixon
Published 15 January 2008 Volume 2007:3(6) Pages 1097—1104
Saba Woldemichael Masho1, Cun-Lin Wang2, Daniel E Nixon3
1Department of Epidemiology and Community Health, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA; 2Federal Drug Administration, Bethesda, Maryland, USA; 3Virginia Commonwealth University HIV/AIDS Center, Department of Internal Medicine, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
Abstract: Highly active antiretroviral therapy has significantly reduced HIV-related morbidity and mortality. Increasingly, fixed-dose antiretroviral combinations with equal or greater potency than traditional antiretrovirals, along with fewer side effects, reduced toxicity, and simplified dosing convenience are being utilized. Tenofovir-emtricitabine (TDF-FTC) represents one of the more recent fixed-dose combinations. In combination with either a ritonavir-boosted protease inhibitor or a non-nucleoside reverse transcriptase inhibitor, TDF-FTC is a preferred choice in recent treatment guidelines on the basis of demonstrated potency in randomized clinical trials, one-pill-a-day dosing convenience, and relatively low toxicity. In addition, the drug is active against hepatitis B virus. Caution must be exercised in patients with renal insufficiency, or when the drug is used with certain other drugs. This manuscript reviews the use of TDF-FTC in the treatment of HIV.
Keywords: tenofovir, emtricitabine, Truvada, TDF, FTC, antiretroviral agent